UK markets open in 5 hours 52 minutes
NIKKEI 225
38,150.45 -123.60 (-0.32%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
79.21 +0.21 (+0.27%) GOLD FUTURES
2,334.30 +23.30 (+1.01%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
46,123.93 -1,892.72 (-3.94%)
Oscotec Inc. (039200.KQ)
KOSDAQ - KOSDAQ Delayed price. Currency in KRW
Add to watchlist
As of 09:48AM KST. Market open.
| Previous close | 30,650.00 |
| Open | 30,450.00 |
| Bid | 30,400.00 x N/A |
| Ask | 30,450.00 x N/A |
| Day's range | 29,900.00 - 30,950.00 |
| 52-week range | 18,000.00 - 36,000.00 |
| Volume | |
| Avg. volume | 504,244 |
| Market cap | 855.7B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 10 May 2024 - 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireFDA Grants Orphan Drug Designation to Cevidoplenib for ITP
Oscotec Inc. has secured orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for its SYK inhibitor, Cevidoplenib, to treat immune thrombocytopenia (ITP).
PR NewswireOscotec/ADEL Initiates First-in-Human Dosing in Ph1 of Anti-MTBR Tau Antibody ADEL-Y01 In Alzheimer's Disease
Oscotec Inc. and ADEL Inc. announced the dosing of the first healthy participant in its first-in-human study of ADEL-Y01 for the treatment of Alzheimer's disease (AD).
© 2024 Yahoo. All rights reserved.